Trial Profile
Real ‐ life use, effectiveness, safety, and quality of life following cabazitaxel in metastatic castration ‐ resistant prostate cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Nov 2019
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms FUJI
- 13 Nov 2019 Results to evaluate the effectiveness and safety of cabazitaxel in the treatment of mCRPC patients published in the British Journal of Cancer
- 24 Sep 2018 New trial record
- 26 Aug 2018 Results presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management